A Phase 1/2, Open-label, Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CC-90011 in Combination with Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia (AML) and Treatment
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Celgene Corporation
Start Date
March 22, 2022
End Date
December 31, 2022
Administered By
Duke Cancer Institute
Awarded By
Celgene Corporation
Start Date
March 22, 2022
End Date
December 31, 2022